CoChat

Cost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction

Sandhu, Alexander T., Ollendorf, Daniel A., Chapman, Richard H., Pearson, Steven D., Heidenreich, Paul A. · 2016 · Annals of Internal Medicine
Cited by 80

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction. OBJECTIVE: To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure. DESIGN: Markov decision model. DATA SOURCES: Clinical trials, observational analyses, reimbursement data from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables. TARGET POPULATION: Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Treatment with sacubitril-valsartan or lisinopril. OUTCOME MEASURES: Life-years, quality-adjusted life-years (QALYs), costs, heart failure hospitalizations, and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The sacubitril-valsartan group experienced 0.08 fewer heart failure hospitalization, 0.69 additional life-year, 0.62 additional QALY, and $29 203 in incremental costs, equating to a cost per QALY gained of $47 053. The cost per QALY gained was $44 531 in patients with NYHA class II heart failure and $58 194 in those with class III or IV heart failure. RESULTS OF SENSITIVITY ANALYSIS: Sacubitril-valsartan treatment was most sensitive to the duration of improved outcomes, with a cost per QALY gained of $120 623 if the duration was limited to the length of the trial (median, 27 months). No variations in other parameters caused the cost to exceed $100 000 per QALY gained. LIMITATION: The benefit of sacubitril-valsartan is based on a single clinical trial. CONCLUSION: Treatment with sacubitril-valsartan provides reasonable value in reducing cardiovascular mortality and morbidity in patients with NYHA class II to IV heart failure. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs and Institute for Clinical and Economic Review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m16-0057

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 37

  1. 10.1161/HHF.0b013e318291329a · DOI · Paper page
  2. 10.1016/j.ccl.2013.09.002 · DOI · Paper page
  3. 10.1177/1060028015593093 · DOI
  4. 10.1016/j.jacc.2013.05.019 · DOI · Paper page
  5. 10.1016/j.amjcard.2004.08.097 · DOI
  6. 10.1016/j.jacc.2014.03.016 · DOI · Paper page
  7. 10.1002/14651858.CD003040.pub2 · DOI · Paper page
  8. 10.1093/eurheartj/ehv186 · DOI · Paper page
  9. 10.1001/archinte.158.10.1081 · DOI · Paper page
  10. 10.1016/j.ahj.2014.11.007 · DOI
  11. 10.1016/j.ehj.2004.07.007 · DOI
  12. Arias E, 2013, Natl Vital Stat Rep, 61, 1
  13. 10.1161/CIRCOUTCOMES.110.957225 · DOI · Paper page
  14. 10.1111/j.1524-4733.2008.00425.x · DOI
  15. 10.1056/NEJMc1509753 · DOI · Paper page
  16. 10.7326/M15-2587 · doi:10.7326/m15-2587
  17. 10.1161/CIRCHEARTFAILURE.116.002837 · DOI
  18. 10.1016/j.jchf.2016.02.012 · DOI
  19. 10.11909/j.issn.1671-5411.2015.05.010 · DOI
  20. 10.1002/phar.1629 · DOI
  21. 10.1016/j.jacc.2015.01.033 · DOI
  22. 10.1093/eurheartj/ehu501 · doi:10.1093/eurheartj/ehu501
  23. 10.1056/NEJM199108013250501 · DOI · Paper page
  24. 10.1016/0002-9149(92)90683-P · DOI
  25. 10.1016/S0735-1097(00)01025-1 · DOI
  26. 10.1001/jamacardio.2016.1747 · DOI · Paper page
  27. 10.1016/j.jchf.2016.02.007 · DOI
  28. 10.1001/jamainternmed.2015.7661 · DOI
  29. 10.1016/S0735-1097(16)31350-X · doi:10.1016/s0735-1097(16)31350-x
  30. 10.1016/S0140-6736(03)13800-7 · DOI · Paper page
  31. 10.1053/euhj.1998.1098 · DOI · Paper page
  32. 10.1001/jama.2015.17632 · DOI
  33. 10.1016/j.amjcard.2006.08.065 · DOI
  34. 10.2165/11314830-000000000-00000 · DOI · Paper page
  35. 10.1093/eurheartj/ehv330 · DOI · Paper page
  36. 10.1016/j.ahj.2006.11.010 · DOI
  37. 10.1016/j.amjcard.2012.05.059 · DOI

Cited by

Metadata

Authors
Sandhu, A. T., Ollendorf, D. A., Chapman, R. H., Pearson, S. D., & Heidenreich, P. A.
Venue
Annals of Internal Medicine
Published
2016-11-15
Volume
165
Issue
10
Pages
681-689
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2517239280
Cited by
80
References
7
FWCI
8.47
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.